Benzinga | Apr 12, 2021 09:20AM EDT

Hoth Therapeutics Completes HT-001 Formulation Development

Today, Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed the formulation for HT-001, a treatment for cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR inhibitor therapies.